SCHEDULE 13G/A: Halpern Trust Discloses 9.6% Stake in Eterna Therapeutics, Awaiting Further Share Issuance

John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, have disclosed a 9.6% beneficial ownership stake in Eterna Therapeutics Inc., with additional shares pending stockholder approval.

Summary

• John D. Halpern and Katherine H. Halpern, acting as trustees of the John D. Halpern Revocable Trust, collectively beneficially own 5,971,830 shares of Eterna Therapeutics Inc. (now Ernexa Therapeutics Inc.) common stock.
• This ownership represents 9.6% of the company's total outstanding common stock.
• The beneficial ownership comprises 5,856,830 shares of common stock directly held by the Trust and 115,000 shares issuable upon the exercise of a pre-funded common stock purchase warrant.
• The 9.6% ownership calculation is based on a total of 62,478,763 shares, which includes 62,363,763 shares reported as outstanding in the Issuer's Quarterly Report on Form 10-Q as of May 7, 2025, plus the 115,000 warrant shares exercisable within 60 days.
• The document indicates that additional shares will be issued to the Trust under a Securities Purchase Agreement dated March 31, 2025, contingent upon receiving stockholder approval at the Issuer's annual meeting scheduled for June 2, 2025.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive, and potentially increasing investment by a trust, suggesting confidence in the company. The mention of a future share issuance via a Securities Purchase Agreement, pending shareholder approval, implies a strategic capital transaction. The certification that the shares are not held for control purposes is standard for a 13G.

Positives

• The disclosure of a significant 9.6% stake by the John D. Halpern Revocable Trust indicates a substantial and committed investment in Eterna Therapeutics Inc.
• The potential for additional share issuance to the Trust, pending stockholder approval, suggests ongoing financial support or strategic alignment from a key investor.

Risks

• The issuance of additional shares to the Trust under the Securities Purchase Agreement is contingent on stockholder approval at the June 2, 2025 annual meeting, introducing a dependency for the full transaction to materialize.
• The future issuance of additional shares could lead to dilution for existing shareholders, depending on the terms and volume of the new issuance.

Future Outlook

The document indicates that additional shares will be issued to the John D. Halpern Revocable Trust pursuant to a Securities Purchase Agreement, contingent upon stockholder approval at the annual meeting scheduled for June 2, 2025.

Industry Context

This filing represents a significant passive investment by a trust in Eterna Therapeutics Inc., a company whose name suggests involvement in the biotechnology or pharmaceutical sector. Such substantial investments by trusts or institutional entities can signal confidence in the company's long-term prospects within its industry, although the filing itself does not provide specific operational or strategic details to assess broader industry trends.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory disclosure of beneficial ownership exceeding 5% by passive investors. It does not contain financial performance metrics or operational data that would allow for a direct comparison to industry standards or specific comparable companies' results.
• The 9.6% beneficial ownership stake is a substantial position for a single trust, indicating a significant commitment, which is common for long-term, passive investors in the biotech or healthcare sector.

Stakeholder Impact

• Shareholders: Potential for dilution if the additional shares from the Securities Purchase Agreement are issued, but also a signal of continued investor confidence from a significant shareholder.

Next Steps

• Stockholder approval at the Issuer's annual meeting on June 2, 2025, for the issuance of additional shares to the Trust under the Securities Purchase Agreement.

Key Dates

Keywords

Eterna Therapeutics, Ernexa Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Shareholder, Investment, Trust, Warrant, SEC Filing, Equity Stake, Securities Purchase Agreement